FR2846969A1 - Nouveaux vecteurs moleculaires amphiphiles fluorocarbones a usage biomedical et medical - Google Patents

Nouveaux vecteurs moleculaires amphiphiles fluorocarbones a usage biomedical et medical

Info

Publication number
FR2846969A1
FR2846969A1 FR0214077A FR0214077A FR2846969A1 FR 2846969 A1 FR2846969 A1 FR 2846969A1 FR 0214077 A FR0214077 A FR 0214077A FR 0214077 A FR0214077 A FR 0214077A FR 2846969 A1 FR2846969 A1 FR 2846969A1
Authority
FR
France
Prior art keywords
chain
active agent
moiety
fluorinated hydrocarbon
hydrophilizing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
FR0214077A
Other languages
English (en)
Inventor
Bernard Pucci
Ange Polidori
Pepin Christiane Contino
Gregory Durand
Sylvain Jasseron
Sandrine Perino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
D AVIGNON ET DES PAYS DU, University of
Universite dAvignon et des Pays de Vaucluse
Original Assignee
D AVIGNON ET DES PAYS DU, University of
Universite dAvignon et des Pays de Vaucluse
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by D AVIGNON ET DES PAYS DU, University of, Universite dAvignon et des Pays de Vaucluse filed Critical D AVIGNON ET DES PAYS DU, University of
Priority to FR0214077A priority Critical patent/FR2846969A1/fr
Priority to EP03782534A priority patent/EP1558630A2/fr
Priority to JP2004550759A priority patent/JP2006520741A/ja
Priority to AU2003290170A priority patent/AU2003290170A1/en
Priority to US10/533,983 priority patent/US20060167223A1/en
Priority to PCT/FR2003/003336 priority patent/WO2004043993A2/fr
Publication of FR2846969A1 publication Critical patent/FR2846969A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

L'invention a pour objet des composés répondant à la formule (I) ci-dessous :dans laquelle :PA représente un principe actif ;x représente un entier choisi parmi 0 et 1 ;X représente une chaîne peptidique ;AA1, AA2, AA3 représentent chacun un acide aminé ;a2, a3 représentent chacun un entier choisi parmi 0 et 1 ;R représente un groupement choisi parmi :- toute molécule susceptible d'être reconnue par la cible du principe actif PA,et- un agent hydrophile permettant la modulation de la balance HLB de la molécule de formule (I),Y représente une chaîne hydrocarbonée fluorée en C4-C12 comportant ungroupement- NH-, -O-CO-NH-, S ou O.
FR0214077A 2002-11-08 2002-11-08 Nouveaux vecteurs moleculaires amphiphiles fluorocarbones a usage biomedical et medical Withdrawn FR2846969A1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
FR0214077A FR2846969A1 (fr) 2002-11-08 2002-11-08 Nouveaux vecteurs moleculaires amphiphiles fluorocarbones a usage biomedical et medical
EP03782534A EP1558630A2 (fr) 2002-11-08 2003-11-07 Nouveaux vecteurs moleculaires amphiphiles fluorocarbones a usage biomedical et medical
JP2004550759A JP2006520741A (ja) 2002-11-08 2003-11-07 生物医学的及び医学的使用のための新規な両親媒性（ａｍｐｉｐｈｉｌｉｃ）フッ素化炭化水素分子ベクター
AU2003290170A AU2003290170A1 (en) 2002-11-08 2003-11-07 Novel ampiphilic fluorocarbon molecular vectors for biomedical and medical use
US10/533,983 US20060167223A1 (en) 2002-11-08 2003-11-07 Novel ampiphilic fluorocarbon molecular vectors for biomedical and medical use
PCT/FR2003/003336 WO2004043993A2 (fr) 2002-11-08 2003-11-07 Nouveaux vecteurs moleculaires amphiphiles fluorocarbones a usage biomedical et medical

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0214077A FR2846969A1 (fr) 2002-11-08 2002-11-08 Nouveaux vecteurs moleculaires amphiphiles fluorocarbones a usage biomedical et medical

Publications (1)

Publication Number Publication Date
FR2846969A1 true FR2846969A1 (fr) 2004-05-14

Family

ID=32116516

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0214077A Withdrawn FR2846969A1 (fr) 2002-11-08 2002-11-08 Nouveaux vecteurs moleculaires amphiphiles fluorocarbones a usage biomedical et medical

Country Status (6)

Country Link
US (1) US20060167223A1 (fr)
EP (1) EP1558630A2 (fr)
JP (1) JP2006520741A (fr)
AU (1) AU2003290170A1 (fr)
FR (1) FR2846969A1 (fr)
WO (1) WO2004043993A2 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015145417A1 (fr) 2014-03-28 2015-10-01 Ilan Ziv Composés et procédés pour l'administration transmembranaire de molécules
US9889202B2 (en) 2014-03-28 2018-02-13 Aposense Ltd. Compounds and methods for trans-membrane delivery of molecules
US9993563B2 (en) 2014-03-28 2018-06-12 Aposense Ltd. Compounds and methods for trans-membrane delivery of molecules
US11230710B2 (en) 2017-01-09 2022-01-25 Aposense Ltd Compounds and methods for trans-membrane delivery of molecules
US11318206B2 (en) 2014-03-28 2022-05-03 Aposense Ltd Compounds and methods for trans-membrane delivery of molecules

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050182060A1 (en) * 2004-02-13 2005-08-18 Kelly Michael G. 2-Substituted and 4-substituted aryl nitrone compounds
GB0408164D0 (en) * 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
FR2883563B1 (fr) * 2005-03-24 2007-06-01 Ts Pharma Sarl Nouveaux vecteurs cationiques bolaformes hemifluorocarbones et leurs applications
US20140065223A1 (en) * 2011-03-31 2014-03-06 Jeanette Libera-Koerner Perfluorinated compounds for the non-viral transfer of nucleic acids
US9694084B2 (en) 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
JP6815318B2 (ja) 2014-12-23 2021-01-20 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド 二官能性分子によって標的化タンパク質分解を誘導する方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0345867A1 (fr) * 1988-06-08 1989-12-13 ENIRICERCHE S.p.A. Peptides synthétiques à activité immunologique, utiles dans la préparation des vaccins contre la malaria
WO1992004371A1 (fr) * 1990-09-07 1992-03-19 Ferring Peptide Research Partnership Kb Inhibiteurs de la kininogenase
WO1999047545A2 (fr) * 1998-03-19 1999-09-23 Vertex Pharmaceuticals Incorporated Inhibiteurs de caspases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2694559B1 (fr) * 1992-08-06 1994-10-28 Atta Nouveaux dérivés amphiphiles d'aminoacides ou de peptides, leur procédé de préparation et leur utilisation dans des préparations à usage biomédical.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0345867A1 (fr) * 1988-06-08 1989-12-13 ENIRICERCHE S.p.A. Peptides synthétiques à activité immunologique, utiles dans la préparation des vaccins contre la malaria
WO1992004371A1 (fr) * 1990-09-07 1992-03-19 Ferring Peptide Research Partnership Kb Inhibiteurs de la kininogenase
WO1999047545A2 (fr) * 1998-03-19 1999-09-23 Vertex Pharmaceuticals Incorporated Inhibiteurs de caspases

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHAUDIER Y ET AL: "Synthesis and preliminary assessments of hybrid hydrocarbon-fluorocarbon anionic and non-ionic surfactants", TETRAHEDRON LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 42, no. 21, 21 May 2001 (2001-05-21), pages 3583 - 3585, XP004238694, ISSN: 0040-4039 *
GUEDJ C ET AL: "Vesicles and other supramolecular systems from biocompatible synthetic glycolipids with hydrocarbon and/or fluorocarbon chains.", CHEMISTRY AND PHYSICS OF LIPIDS, vol. 72, no. 2, 1994, pages 153 - 173, XP009013441, ISSN: 0009-3084 *
JASSERON SYLVAIN ET AL: "Synthesis and preliminary biological assessments of RGD bearing biocompatible telomers.", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 12, no. 7, 2002, 8 April, 2002, pages 1067 - 1070, XP002247711, ISSN: 0960-894X *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015145417A1 (fr) 2014-03-28 2015-10-01 Ilan Ziv Composés et procédés pour l'administration transmembranaire de molécules
EP3125946A4 (fr) * 2014-03-28 2017-11-01 Aposense Ltd. Composés et procédés pour l'administration transmembranaire de molécules
US9889202B2 (en) 2014-03-28 2018-02-13 Aposense Ltd. Compounds and methods for trans-membrane delivery of molecules
US9993563B2 (en) 2014-03-28 2018-06-12 Aposense Ltd. Compounds and methods for trans-membrane delivery of molecules
AU2015237746B2 (en) * 2014-03-28 2020-01-30 Aposense Ltd. Compounds and methods for trans-membrane delivery of molecules
US11318206B2 (en) 2014-03-28 2022-05-03 Aposense Ltd Compounds and methods for trans-membrane delivery of molecules
US11230710B2 (en) 2017-01-09 2022-01-25 Aposense Ltd Compounds and methods for trans-membrane delivery of molecules

Also Published As

Publication number Publication date
WO2004043993A2 (fr) 2004-05-27
US20060167223A1 (en) 2006-07-27
AU2003290170A8 (en) 2004-06-03
JP2006520741A (ja) 2006-09-14
AU2003290170A1 (en) 2004-06-03
WO2004043993A3 (fr) 2004-07-29
EP1558630A2 (fr) 2005-08-03

Similar Documents

Publication Publication Date Title
ES2201188T3 (es) Conjugados moleculares ionicos de derivados n-acilados de poli(2-amino-2-deoxi-d-glucosa) y polipeptidos.
Nierhaus et al. Identification of the chloramphenicol-binding protein in Escherichia coli ribosomes by partial reconstitution
US6262253B1 (en) Vitamin B12 conjugates with gcsf, analogues thereof and pharmaceutical compositions
CN101242859B (zh) 作为聚合物缀合前药中的连接团的n,n-二（羟乙基）甘氨酰胺
ES2532116T3 (es) Péptidos derivados con A-B-C-D y sus usos terapéuticos
RU2006107546A (ru) Производные сиаловой кислоты для получения производных белков и конъюгации
FR2846969A1 (fr) Nouveaux vecteurs moleculaires amphiphiles fluorocarbones a usage biomedical et medical
YU48703A (sh) Novi interferonu beta-slični molekuli
WO2005056760A3 (fr) Hormone stimulant le follicule humain glycopegyle
AU2019275610A1 (en) Improved peptide pharmaceuticals
WO2006031811A3 (fr) Interferon alpha glycopegyle
EP3302567B1 (fr) Promédicaments comprenant un conjugué d'acide hyaluronique, un lieur d'agoniste double de glp-1/glucagon
WO2001058493A8 (fr) Conjugates of follicle stimulating hormones
WO2002055532A3 (fr) Molecules d'hormone de croissance ameliorees
NO324045B1 (no) Forbindelser, farmasoytisk blanding og den anvendelse og diagnostisk anordning som omfatter forbindelsene
CA2594970A1 (fr) Conjugues d'un polypeptide et d'un oligosaccharide
AU2012255119A1 (en) Improved peptide pharmaceuticals for insulin resistance
HUT75058A (en) Amplification of the vitamin b12 uptake system using polymers
RU2009129961A (ru) АНАЛОГИ ГЛЮКАГОНА, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ РАСТВОРИМОСТЬЮ В БУФЕРАХ С ФИЗИОЛОГИЧЕСКИМ ЗНАЧЕНИЕМ pH
US20200362007A1 (en) Novel GLP-1 Analogues
CA2619036A1 (fr) Conjugues d'amidon hydroxyalkyle et d'une substance active, prepares par ligature chimique par l'intermediaire de la thiazolidine
US7851618B2 (en) Aminated complex-type sugar chain derivatives and process for the production thereof
Braun et al. Bioresponsive release of insulin-like growth factor-I from its PEGylated conjugate
EP2926829B1 (fr) Lieur à chaîne glucidique liée, composé contenant un lieur à chaîne glucidique liée et substance physiologiquement active ou son sel, et son procédé de production
US7829074B2 (en) Hydroxypatite-targeting poly(ethylene glycol) and related polymers

Legal Events

Date Code Title Description
AU Other action affecting the ownership or exploitation of an industrial property right
ST Notification of lapse

Effective date: 20070731